Indeed, PSMA is overexpressed up to 1000 times in cancer cells more than normal prostate cells, and its level is increased in parallel with the tumor dedifferentiation, with a pathological overexpression also in several other malignancies, such as kidney cancer, bladder cancer, or hepatocellular carcinoma [16,17]. This evidence concerns the gene FOLH1 and neoplasm.